In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.
|Articles|December 31, 2011
- Winter 2011
- Volume 10
- Issue 4
From Our Archives: Tissue Banking
Read past CURE article on tumor tissue banking.
Advertisement
filo
You can read more articles on tissue banking from CURE's archive:
International Melanoma Tissue Bank in the Works (Spring 2009 Web exclusive)
A new organization aims to strike back at melanoma by developing the first-ever international melanoma tissue bank... [read more]
Precious Tumor (Summer 2007)
Tissue collection is nothing new. Each day, biospecimens are deposited at blood banks, at sperm laboratories, in pathology labs, and other locations... [read more]
Articles in this issue
almost 15 years ago
Tips to Manage Dental Issues During Cancer Therapyalmost 15 years ago
Resources to Ease the Financial Burden of Canceralmost 15 years ago
What’s Next for My Life?almost 15 years ago
Respite Care for Caregiversalmost 15 years ago
Brighter Horizons for Hodgkin Lymphoma Patientsalmost 15 years ago
Medical Debt: An Unspoken Side Effect of Cancer Carealmost 15 years ago
Eat Gingerly for Your Healthalmost 15 years ago
Why Banks Need Your Tissue for Researchalmost 15 years ago
Consider Dental Issues Before Beginning Cancer TreatmentAdvertisement
Related to this article
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Advertisement
Advertisement
Trending on CURE
1
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
2
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
3
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
4
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
5